News

Apellis Pharmaceuticals Sees Record Growth in 2024 Results

Apellis Pharmaceuticals Sees Record Growth in 2024 Results

Apellis Pharmaceuticals Shows Incredible Growth in 2024

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), has recently shared its financial results demonstrating a remarkable increase in revenue over the previous year. With a reported revenue of $781.4 million for the full year 2024, Apellis showcases an astounding 97% growth from the previous year. This growth is primarily fueled by its innovative therapies SYFOVRE and EMPAVELI, leading the charge in transforming treatment paradigms in their respective markets.

Revenue Breakdown for 2024

The noteworthy revenue figures consist of net product revenues from SYFOVRE totaling $611.9 million and EMPAVELI bringing in $98.1 million. SYFOVRE, which is designed to treat geographic atrophy secondary to age-related macular degeneration, continues to gain traction, demonstrating the effectiveness and reliable demand for targeted therapies.

Key Financial Highlights

  • Total revenues for the fourth quarter of 2024 reached $212.5 million, comprising $167.8 million from SYFOVRE and $23.4 million from EMPAVELI.
  • Apellis ended the year with $411.3 million in cash, which is projected to be sufficient to fund operations through to profitability going forward.
  • The net loss for the fourth quarter was significantly reduced to $36.4 million, compared to $88.5 million for the same period in 2023, highlighting improved operational efficiency.

Advancements in Novel Therapies

In addition to financial growth, Apellis Pharmaceuticals has made considerable strides in expanding its product pipeline. The company has submitted a supplemental new drug application (sNDA) for EMPAVELI targeting C3 glomerulopathy (C3G) and primary immune complex glomerulonephritis (IC-MPGN), with the U.S. launch anticipated in the second half of 2025, pending approval. Furthermore, two Phase 3 trials for EMPAVELI are expected to start in late 2025.

Innovative Approaches to Disease Treatment

Apellis is continuously working on innovative treatments and exploring the synergy between SYFOVRE and APL-3007, an upcoming siRNA treatment. This combination aims to enhance complement inhibition, targeting the complement system responsible for various pathological conditions in the retina. Such developments emphasize Apellis' commitment to advanced therapeutic solutions and their drive to push the boundaries of science in medicine.

Organizational Developments

Apellis has witnessed considerable changes within its executive leadership. David Acheson has assumed the position of executive vice president of commercial, succeeding the former COO Adam Townsend, while Keli Walbert has joined the company’s Board of Directors, bringing two decades of biopharmaceutical experience to the table.

Looking to the Future

With solid financial backing and a growing portfolio of innovative therapies, Apellis Pharmaceuticals is well-positioned for sustained growth. Their strategic focus on addressing significant unmet needs in eye care and rare diseases reflects their dedication not only to shareholders but also to patient outcomes.

Frequently Asked Questions

What are the primary products of Apellis Pharmaceuticals?

Apellis Pharmaceuticals primarily focuses on SYFOVRE for geographic atrophy and EMPAVELI for various complement-related diseases, including PNH and C3G.

How much revenue did Apellis report for 2024?

Apellis reported a total revenue of $781.4 million for the full year 2024, marking a 97% increase from the previous year.

What is the anticipated launch timeline for EMPAVELI?

The anticipated launch of EMPAVELI for C3G and IC-MPGN is projected for the second half of 2025, pending regulatory approval.

Who are the key executives at Apellis Pharmaceuticals?

Key executives include Cedric Francois, CEO, and David Acheson, who is now the executive vice president of commercial.

What innovations is Apellis working on?

Apellis is advancing several treatments, including a novel siRNA therapy APL-3007, which targets the complement system alongside SYFOVRE.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Avoid FOGs: Illinois Water's Holiday PSA

Updated Category News Views 112

Don't Ignore the Kitchen Sink This Holiday You ever poured something down the drain and just prayed it wouldn't come back to bite you later? Well, Illinois American Water is throwing up a big, red flag about doing exactly that during the holidays. When we're all busy passing the gravy boat and diving into festive feasts, it's easy to forget the after-party might just turn...

Continue Reading
Panduit's AI Cooling Lab Boosts Data Center Innovation

Updated Category News Views 140

Innovation in Cooling: Panduit's Latest Move You hear "AI" and "data center" together and you know it's not gonna be business as usual. Here's Panduit throwing another log on the fire with their newly minted AI Cooling Lab. Panduit's a big cheese in the electrical and network infrastructure world. They've taken their Thermal Lab, given it a face-lift, and now, they’re...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 163

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
CSMI Boosts CT's Cybersecurity for Defense Sector

Updated Category News Views 109

Paving the Way for Cybersecurity Excellence Out in chilly Connecticut, CSMI made a mark. The State's Office of Manufacturing picked them to join the advisory council for the Defense CyberSecure Program (CT-DCP). It ain’t just a pat on the back; it's a big deal for the region's defense and aerospace manufacturing gang. Connecticut's got its eyes set on beefing up its...

Continue Reading
Intel Faces Class Action Over Alleged Securities Fraud

Updated Category News Views 122

Intel's Legal Predicament: Decoding the Lawsuit Saddle up, folks, because Intel (NASDAQ: INTC) has found itself tangled in legal vines again. This ain't their first rodeo, and probably won't be their last. We're looking at a hefty class action lawsuit rallying on claims that Intel misled investors with optimistic yarns about their health. SBS Law, waving the litigation...

Continue Reading
Chicago Auto Show: Run & Explore Indoors This February

Updated Category News Views 136

Nobody’s thinking about running laps when they walk into a colossal auto show, but the Chicago Auto Show isn't letting the pedal ease off the gas. Swing by on February 14, folks, for something not typically seen on the floors of McCormick Place. Run participants have got one hour to log as many miles as they can on the 2.4-mile loop right inside the show. Why a Running...

Continue Reading
Radiotherapy Suit Challenges New EviCore Guidelines

Updated Category News Views 100

Turning Up the Heat on EviCore Winter Park, Florida—home of sunshine, oranges, and now a heated legal standoff. On November 16, 2026, the Radiotherapy Access Alliance dropped a bombshell lawsuit against EviCore over its recent guideline flip-flop. EviCore reversed its stance on low-dose radiation therapy (LDRT) for arthritis and other pesky pain, leaving patients—and...

Continue Reading
Main Capital Partners Backs TaskRay: Salesforce Expansion

Updated Category News Views 111

Investing in Transformation Main Capital Partners has thrown in with TaskRay, joining hands with Cloud Coach and JustOn to shake up customer delivery on Salesforce. These three are cooking up an ambitious AI-driven platform that's gunning to streamline from project management to financial operations. Main's stepping into this mix with a mindset that aligns with over 800...

Continue Reading
equipifi's BNPL Shop: New Ammo for Credit Unions

Updated Category News Views 106

equipifi's 'Shop': The Big Play in Banking Look, here’s the deal—equipifi just lobbed a new grenade into the finance battlefield, arming credit unions and community banks with 'Shop', their own Buy Now, Pay Later (BNPL) platform. The goal? To put them toe-to-toe with the big fintech wolves—something these smaller guys desperately needed. It's a meaty move, no...

Continue Reading
Kinross Gold Fraud Lawsuit: What Shareholders Need to Know

Updated Category News Views 58

Kinross Gold's Legal Quagmire There's a fresh storm brewing for Kinross Gold Corporation (NYSE: KGC), and it ain't the kind investors enjoy riding. You see, the company is up to its neck in a class action lawsuit, courtesy of Schall, Brown & Schwartz LLP—a big-name shareholder rights litigation outfit. The gripe? Alleged securities fraud, violating §§10(b) and 20(a)...

Continue Reading

Top 5 Most Recently Viewed Articles

SiriusPoint Declares Cash Dividend on Series B Preference Shares

Updated Category News Views 123

SiriusPoint Declares Quarterly Cash Dividend for Investors In a significant move for its shareholders, SiriusPoint Ltd. has recently revealed the approval of a quarterly cash dividend of $0.50 per share for the 8.00% Resettable Fixed Rate Preference Shares, Series B. This decision, endorsed by the Audit Committee of the Board of Directors, showcases the company's...

Continue Reading
Urban One Welcomes New Leadership as CEO David Kantor Retires

Updated Category News Views 435

Changes in Leadership at Urban One Urban One has made a significant announcement regarding changes at the helm of its audio division. Currently, the company bids farewell to CEO David Kantor, a well-respected figure in the industry, whose tenure has shaped Urban One into a key player in audio entertainment. Kantor's retirement, set for early 2025, opens the door for new...

Continue Reading
Mattamy Homes Expands Presence with New Division in Florida

Updated Category News Views 502

Mattamy Homes Expands Operations in Florida Company strengthens regional focus to enhance customer service, empower teams and drive future expansion Mattamy Homes US has officially launched a new division centered in Southwest Florida. This strategic initiative is set to improve operational agility, allowing Mattamy to provide exceptional service to its customers...

Continue Reading
Eloro Resources Secures $3.78 Million in Latest Placement

Updated Category News Views 235

Eloro Resources Completes Private Placement Successfully Eloro Resources Ltd. (TSX: ELO; OTCQX: ELRRF; FSE: P2QM) has announced a significant achievement in its funding efforts. The company successfully closed its non-brokered private placement offering, concluding with a total of 4,200,000 units sold. This move resulted in gross proceeds of approximately $3,780,000,...

Continue Reading
Groundbreaking Global Health Exhibition Set to Transform Healthcare

Updated Category News Views 54

Global Health Exhibition Promises Unmatched Innovation Tomorrow marks the opening of the much-anticipated Global Health Exhibition, an international healthcare event attracting over 100,000 professionals dedicated to health and patient care. Spanning across three days, this premier event will host an impressive assembly of over 1,200 exhibiting companies and brands,...

Continue Reading